Therefore, it is essential to elucidate the mechanism of the PI3K signaling pathway in breast cancer and explore the potential of PI3K inhibitors in the treatment of different subtypes of breast cancer, alone or combined with other therapies in both early and metastatic settings. This evidence concerns the gene PIK3CA and breast carcinoma.